Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 2/20 | 0.61 |
| ▸ | F2 | P00734 | 1/20 | 0.61 |
| ▸ | PLG | P00747 | 1/20 | 0.61 |
| ▸ | CTSG | P08311 | 1/20 | 0.61 |
| ▸ | CMA1 | P23946 | 1/20 | 0.61 |
| ▸ | CTRC | Q99895 | 1/20 | 0.61 |
| ▸ | RGS4 | P49798 | 1/20 | 0.61 |
| ▸ | CASP3 | P42574 | 1/20 | 0.58 |
| ▸ | GSK3A | P49840 | 1/20 | 0.57 |
| ▸ | GSK3B | P49841 | 1/20 | 0.57 |
| ▸ | MGLL | Q99685 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | ALDH2 | P05091 | 2/20 | 0.52 |
| ▸ | ALDH3A1 | P30838 | 2/20 | 0.52 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.52 |
| ▸ | CES1 | P23141 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28570724 | 0.82 | CYP1B1 (0.58) | ELANEF2PLGCTSGCMA1 | |
| SCHEMBL30472950 | 0.80 | CASP3 (0.85) | ELANEF2PLGCTSGCMA1 | |
| SCHEMBL326305 | 0.80 | CASP3 (0.85) | ELANEF2PLGCTSGCMA1 | |
| SCHEMBL5049894 | 0.80 | ELANE (0.64) | ELANEF2PLGCTSGCMA1 | |
| SCHEMBL13896937 | 0.78 | ELANE (0.61) | ELANEF2PLGCTSGCMA1 | |
| SCHEMBL18979915 | 0.78 | ELANE (0.61) | ELANEF2PLGCTSGCMA1 | |
| SCHEMBL8133525 | 0.78 | ELANE (0.61) | ELANEF2PLGCTSGCMA1 | |
| SCHEMBL17114059 | 0.77 | KMT2A (0.42) | CMA1RGS4CASP3MEN1KMT2A | |
| SCHEMBL20437111 | 0.77 | KMT2A (0.51) | RGS4MEN1KMT2ANPSR1ALDH1A1 | |
| SCHEMBL13793073 | 0.77 | ELANE (0.82) | ELANEF2PLGCTSGCMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10453420-B2 | Base film, laminated structure including the same, and display device | LG CHEM, LTD. (KR) | 2019-10-22 | — | — | US | claimed |
| CN-110317308-A | A kind of preparation method and refractory material of phenolic resin for refractory material | 沙县宏盛塑料有限公司 | 2019-10-11 | — | — | CN | claimed |
| CN-104871118-B | Basement membrane includes the laminar structure and display device of the basement membrane | LG化学株式会社 | 2017-07-18 | — | — | CN | claimed |
| US-20150299841-A1 | BASE FILM, LAMINATED STRUCTURE INCLUDING THE SAME, AND DISPLAY DEVICE | LG CHEM, LTD. (KR) | 2015-10-22 | — | — | US | claimed |
| CN-104871118-A | BASE FILM, AND LAMINATED STRUCTURE AND DISPLAY DEVICE COMPRISING SAME | LG CHEMICAL LTD | 2015-08-26 | — | — | CN | claimed |
| US-11091434-B2 | Type III deiodinase inhibitors and uses thereof | HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (IL) | 2021-08-17 | — | — | US | disclosed |
| US-10453420-B2 | Base film, laminated structure including the same, and display device | LG CHEM, LTD. (KR) | 2019-10-22 | — | — | US | disclosed |
| US-10435365-B2 | Type III deiodinase inhibitors and uses thereof | HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (IL) | 2019-10-08 | — | — | US | disclosed |
| EP-3119768-B1 | 3,4-BROMO OR -SULFONATE SUBSTITUTED 1H-PYRROLE-2,5-DIONE DERIVATIVES AS TYPE III DEIODINASE (DIO3) INHIBITORS FOR TREATING DEPRESSIONS AND CANCER | HADASIT MED RES SERVICE (IL) | 2019-07-31 | — | — | EP | disclosed |
| EP-3119768-B1 | 3,4-BROMO OR -SULFONATE SUBSTITUTED 1H-PYRROLE-2,5-DIONE DERIVATIVES AS TYPE III DEIODINASE (DIO3) INHIBITORS FOR TREATING DEPRESSIONS AND CANCER | HADASIT MED RES SERVICE (IL) | 2019-07-31 | — | — | EP | disclosed |
| US-20180215709-A1 | TYPE III DEIODINASE INHIBITORS AND USES THEREOF | HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (IL) | 2018-08-02 | — | — | US | disclosed |
| US-20180215709-A1 | TYPE III DEIODINASE INHIBITORS AND USES THEREOF | HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (IL) | 2018-08-02 | — | — | US | disclosed |
| US-7488817-B2 | Metal complex protein kinase inhibitors | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2009-02-10 | — | — | US | disclosed |
| US-20080275019-A1 | METAL COMPLEX PROTEIN KINASE INHIBITORS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2008-11-06 | — | — | US | disclosed |
| US-20080096949-A1 | Indazolyl-substituted pyrroline compounds as kinase inhibitors | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC. | 2008-04-24 | — | — | US | disclosed |
| US-20080096949-A1 | Indazolyl-substituted pyrroline compounds as kinase inhibitors | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC. | 2008-04-24 | — | — | US | disclosed |
| US-7329657-B2 | Indazolyl-substituted pyrroline compounds as kinase inhibitors | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2008-02-12 | — | — | US | disclosed |
| US-7304060-B2 | Indazolyl-substituted pyrroline compounds as kinase inhibitors | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2007-12-04 | — | — | US | disclosed |
| US-7304060-B2 | Indazolyl-substituted pyrroline compounds as kinase inhibitors | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2007-12-04 | — | — | US | disclosed |
| US-20050171076-A1 | Metal complex protein kinase inhibitors | TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, THE | 2005-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171076-A1 | Metal complex protein kinase inhibitors | CAMK1, CAMK1G, CAMKK2 | ELANE 4161/4885F2 4090/4885PLG 3708/4885 |
| US-20180215709-A1 | TYPE III DEIODINASE INHIBITORS AND USES THEREOF | TPO, DPP3, HSD17B3 | ELANE 3694/4885F2 3555/4885PLG 2988/4885 |
| US-20080096949-A1 | Indazolyl-substituted pyrroline compounds as kinase inhibitors | MAP2K2, MAP3K20, MAP2K3 | ELANE 4614/4885F2 4671/4885PLG 3766/4885 |
| US-20080275019-A1 | METAL COMPLEX PROTEIN KINASE INHIBITORS | CAMK1, CAMK1G, CAMKK2 | ELANE 4161/4885F2 4090/4885PLG 3708/4885 |
| US-11091434-B2 | Type III deiodinase inhibitors and uses thereof | TPO, DPP3, HSD17B3 | ELANE 3694/4885F2 3555/4885PLG 2988/4885 |
| US-10435365-B2 | Type III deiodinase inhibitors and uses thereof | TPO, DPP3, HSD17B3 | ELANE 3694/4885F2 3555/4885PLG 2988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.